Related Experiment Video
Updated: Apr 18, 2026

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq
Published on: April 19, 2013
Chemerin and prediction of Diabetes mellitus type 2
Thomas Bobbert1, Franziska Schwarz1,2, Antje Fischer-Rosinsky1,2,3
1Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Objective:
Insulin resistance and subclinical inflammation are characteristics in the development of type 2 diabetes mellitus (T2DM). The adipokine chemerin has been associated with both factors. The aim of this study was to analyse whether chemerin predicts T2DM.
Design:
Blood samples of 440 participants of the Metabolic-Syndrome Berlin-Potsdam (MesyBepo) follow-up study without diabetes at baseline were available for chemerin measurement. Mean follow-up of participants was 5·3 years. Glucose metabolism was analysed using oral glucose tolerance test including insulin measurements. Chemerin was measured using a commercially available ELISA.
Results:
Thirty-five individuals developed T2DM during follow-up. Chemerin predicted incident T2DM (Chemerin 1. Tertile: reference, 2. Tertile: OR 2·33 [0·68-7·95]; Chemerin 3. Tertile: OR 3·42 [1·01-11·58] after adjustment for age, sex, BMI, follow-up time, HbA1c, HOMA-IR and WHR). In a secondary analysis, chemerin also predicted worsening of fasting glucose and HbA1c (adjusted for age, sex, BMI, time of follow-up, WHR, HDL cholesterol and triglycerides).
Conclusions:
Our data suggest that chemerin is a weak predictor of T2DM.
Related Concept Videos
Type II Diabetes I: Introduction
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type II Diabetes II: Pathophysiology
Diabetes Mellitus: Type 2 and Gestational
Type I Diabetes II: Pathophysiology
Type I Diabetes I: Introduction

